Publication details

Výsledky léčby nemocných s esenciální trombocytémií a dalšími myeloproliferacemi provázenými trombocytémií-zpráva z registru pacientů léčených Thromboreductinem

Title in English The results of the treatment of patients with essential thrombocythemia and other myeloproliferation-related thrombocythemia-a report of patients treated with Thromboreductin
Authors

PENKA Miroslav SCHWARZ Jiří PAVLÍK Tomáš INDRÁK Karel DOUBEK Michael DULÍČEK P. POSPÍŠILOVÁ D. KISSOVÁ Jarmila JONÁŠOVÁ A. JELÍNKOVÁ Pavla HLUŠÍ A. SCHUTZOVÁ M. ČERNÁ O. BRYCHTOVÁ Yvona NOVÁKOVÁ L. KOŘÍSTEK Zdeněk SEGETHOVÁ J. VOZOBULOVÁ Jaroslava HADAČOVÁ I. HOCHOVÁ I. VOGLOVÁ J. WALTEROVÁ L. BODZÁSOVÁ C. DUŠEK Ladislav

Year of publication 2009
Type Article in Periodical
Magazine / Source Vnitřní Lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords essential thrombocythemia; myeloproliferation; Thromboreductin; patient registry
Description The registry of patients treated with Thromboreductin (anagrelide) in the Czech Republic contains data concerning patients that have been treated using this drug since 2004. As of June 2009, the total number of patients was 549. The current analysis focused mainly on evaluation of anagrelide dosage needed to achieve a complete response in high-risk patients: reduction in platelet count to below 400 x 10(9)/l, which was also considered as reaching the therapeutic goal. The outcomes of the registry confirm that although anagrelide (Thromboreductin) is a very effective platelet-reducing agent, the administration of which is related to a low incidence of adverse effects and complications, the therapeutic goal is not achieved in all cases and or despite a quick treatment response, the therapeutic goal is achieved more slowly.

You are running an old browser version. We recommend updating your browser to its latest version.

More info